Zhao Yun-Qiu, Liu Yong-Jun, Song Lu, Yu Dingyan, Liu Kun, Liu Ke, Gao Bei, Tao Xin-Yi, Xiong Liang-Bin, Wang Feng-Qing, Wei Dong-Zhi
State Key Laboratory of Bioreactor Engineering, Newworld Institute of Biotechnology, East China University of Science and Technology, 130 Meilong Road, Shanghai, 200237, China.
Shanghai Key Laboratory of Molecular Imaging, Shanghai University of Medicine and Health Sciences, Shanghai, 201318, China.
Biotechnol Biofuels Bioprod. 2023 Aug 2;16(1):121. doi: 10.1186/s13068-023-02376-2.
Harnessing engineered Mycolicibacteria to convert cheap phytosterols into valuable steroid synthons is a basic way in the industry for the production of steroid hormones. Thus, C-19 and C-22 steroids are the two main types of commercial synthons and the products of C17 side chain degradation of phytosterols. During the conversion process of sterols, C-19 and C-22 steroids are often produced together, although one may be the main product and the other a minor byproduct. This is a major drawback of the engineered Mycolicibacteria for industrial application, which could be attributed to the co-existence of androstene-4-ene-3,17-dione (AD) and 22-hydroxy-23,24-bisnorchol-4-ene-3-one (HBC) sub-pathways in the degradation of the sterol C17 side chain. Since the key mechanism underlying the HBC sub-pathway has not yet been clarified, the above shortcoming has not been resolved so far.
The key gene involved in the putative HBC sub-pathway was excavated from the genome of M. neoaurum by comparative genomic analysis. Interestingly, an aldolase- encoding gene, atf1, was identified to be responsible for the first reaction of the HBC sub-pathway, and it exists as a conserved operon along with a DUF35-type gene chsH4, a reductase gene chsE6, and a transcriptional regulation gene kstR3 in the genome. Subsequently, atf1 and chsH4 were identified as the key genes involved in the HBC sub-pathway. Therefore, an updated strategy was proposed to develop engineered C-19 or C-22 steroid-producing strains by simultaneously modifying the AD and HBC sub-pathways. Taking the development of 4-HBC and 9-OHAD-producing strains as examples, the improved 4-HBC-producing strain achieved a 20.7 g/L production titer with a 92.5% molar yield and a 56.4% reduction in byproducts, and the improved 9-OHAD producing strain achieved a 19.87 g/L production titer with a 94.6% molar yield and a 43.7% reduction in byproduct production.
The excellent performances of these strains demonstrated that the primary operon involved in the HBC sub-pathway improves the industrial strains in the conversion of phytosterols to steroid synthons.
利用工程改造的分枝杆菌将廉价的植物甾醇转化为有价值的甾体合成子是甾体激素生产行业的一种基本方法。因此,C-19和C-22甾体是两种主要的商业合成子类型,也是植物甾醇C17侧链降解的产物。在甾醇的转化过程中,C-19和C-22甾体通常同时产生,尽管其中一种可能是主要产物,另一种是次要副产物。这是工程改造的分枝杆菌在工业应用中的一个主要缺点,这可能归因于甾醇C17侧链降解过程中雄甾-4-烯-3,17-二酮(AD)和22-羟基-23,24-双降胆甾-4-烯-3-酮(HBC)子途径的共存。由于HBC子途径的关键机制尚未阐明,上述缺点至今尚未得到解决。
通过比较基因组分析,从新金色分枝杆菌的基因组中挖掘出了推测的HBC子途径中涉及的关键基因。有趣的是,一个编码醛缩酶的基因atf1被确定为负责HBC子途径的第一步反应,并且它在基因组中与一个DUF35型基因chsH4、一个还原酶基因chsE6和一个转录调控基因kstR3一起作为一个保守操纵子存在。随后,atf1和chsH4被确定为参与HBC子途径的关键基因。因此,提出了一种更新的策略,即通过同时改造AD和HBC子途径来开发工程改造的C-19或C-22甾体生产菌株。以生产4-HBC和9-OHAD的菌株的开发为例,改良后的4-HBC生产菌株的产量达到20.7 g/L,摩尔产率为92.5%,副产物减少56.4%,改良后的9-OHAD生产菌株的产量达到19.87 g/L,摩尔产率为94.6%,副产物产量减少43.7%。
这些菌株的优异性能表明,参与HBC子途径的主要操纵子提高了工业菌株将植物甾醇转化为甾体合成子的能力。